CRN Projects

Novel Vehicles for Targeted Cardiovascular Repair

Principal Investigators:
Melina R. Kibbe
Samuel I. Stupp
Illustration: Mark E. Seniw


September 2013:

Catalyst Project results in $4.2 million Bioengineering Research Partnership Award to the Institute for BioNanotechnology in Medicine

Co-Principal Investigators: Melina R. Kibbe and Samuel I. Stupp
Co-investigators: C. Shad Thaxton, Urology, and Teng Leong Chew, Cell and Molecular Biology

Atherosclerosis remains the leading cause of death and disability in the United States. Current therapeutic modalities for the treatment of severe coronary and peripheral artery disease include balloon angioplasty and stenting, endarterectomy, or bypass grafting. Unfortunately, a large number of these procedures fail due to the development of arterial restenosis secondary to neointimal hyperplasia.

The overall goal of this CRN Catalyst Project is to launch preliminary research to develop highly innovative, targeted therapeutics delivered by bio-inspired tailorable constructs to prevent restenosis following vascular interventions. We expect to develop biocompatible nano- and microscale therapies that will be delivered systemically at the time of arterial intervention, target the manipulated arterial segment, and deliver molecular therapies and drugs to that site to inhibit restenosis. The platforms proposed are bio-inspired and share common physicochemical properties such that unique aspects of each one may be leveraged by the other to achieve maximal therapeutic efficacy.

Catalyst Project researchers Tyson Moyer (left), PhD candidate in the Stupp group, and Edward S. Moreira, postdoctoral fellow in the Kibbe group.Preliminary data demonstrate the successful synthesis and in vivo targeting of a novel injectable peptide amphiphile (PA) to the site of vascular injury following intra-arterial injection. Overall, we hypothesize that novel, targeted bioengineered therapeutic agents will prevent the development of restenosis following arterial interventions. To investigate this hypothesis, our long-range plan is to synthesize and characterize novel bio-inspired delivery vehicles that are targeted to the site of vascular injury and deliver effective therapeutic agents, evaluate the effect of the targeted engineered therapeutic delivery vehicles on cells from the vascular wall in vitro, and determine the specificity, safety, biocompatibility, and efficacy of the targeted engineered therapeutic delivery vehicles at inhibiting neointimal hyperplasia in vivo.

If successful, these therapies could revolutionize how atherosclerotic arteries are treated and thus represent a paradigm-shifting technology.

Principal Investigators

Melina R. Kibbe

Surgery, Feinberg School of Medicine

Samuel I. Stupp

Materials Science & Engineering, McCormick School of Engineering and Applied Science
Chemistry, Weinberg College of Arts & Sciences
Medicine, Feinberg School of Medicine

CRN catalyzes new research in regenerative medicine using nanotechnology strategies.